About K4DD

The 5-year K4DD program started in November 2012. K4DD is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU), resources of which are composed of a financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.

The overall program consists of four Work Packages in which a total of 25 PhD students and postdocs are performing the research with support from senior researchers of all partners: 9 academic institutes, 7 large pharmaceutical companies and 4 Small-and Medium-sized Enterprises (SMEs).

Total budget of the program is €21 Million. The EFPIA companies' in kind and IMI JU cash contributions are €9.8 Million and €8.3 Million, respectively. The remainder of the funding (€2.9 Million) is provided in kind by the academic partners and SMEs.

With 20 partners from 6 different countries, an efficient and well-defined management structure is essential to ensure the smooth realization of the work packages and project deliverables.

The General Assembly (GA), in which all partners are represented, is the main strategic decision making body of the consortium. The GA meets twice a year. The day-to-day management of the project is addressed by the Project Management Team (PMT), which consists of the Project Coordinator (Bayer Pharma: Dr Anke Mueller-Fahrnow) and the Managing Entitity (Univ of Leiden: Prof Ad IJzerman). The PMT is supported by a dedicated Project Manager (TI Pharma).

Each Work Package within the program is led by one WP leader from EFPIA and one from Academia to ensure efficient cross-talk. The WP leaders are responsible for day-to-day management and (scientific) coordination of their respective WP. To enable monitoring progress across the Work Packages, for each studied target a so-called Target Foster has been nominated by the GA, and which have a seat in the Target Fosters Committee (TFC). The TFC meets every quarter.

Overall scientific progress and quality of the project is monitored by the Executive Board (EB), in which the Project Coordinator, Managing Entity, WP leaders and the chair of the TFC have a seat. The EB meets every quarter.

Finally, K4DD leadership is supported by two external advisory bodies. The Scientific Advisory Board, consisting of 3 renowned scientific experts, critically monitors the scientific progress and overall performance of the project. The Ethics Advisory Board, consisting of 3 professional experts, critically monitor the ethical issues and implications of the science within the project. These experts combined represent an important source of information, especially on external developments that could impact the work of the consortium

K4DD Governance
s